# EDGAR Filing Document

**Accession Number:** 0001822462
**File Stem:** 0001628280-25-031819
**Filing Date:** 2025-6
**Character Count:** 6892
**Document Hash:** f7a641722b14453a7c792677bc08b5d4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-031819.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0001628280-25-031819

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Foghorn Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001822462
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39634
- **FILM NUMBER:** 251053254

**BUSINESS ADDRESS:**
- **STREET 1:** 500 TECHNOLOGY SQUARE
- **STREET 2:** SUITE 700
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-586-3100

**MAIL ADDRESS:**
- **STREET 1:** 500 TECHNOLOGY SQUARE
- **STREET 2:** SUITE 700
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

?xml version='1.0' encoding='ASCII'? fhtx-20250617

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

________________________

**FORM 8-K**

________________________________________________________________________________________________

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): June 17, 2025**

________________________________________________________________________________________________

**Foghorn Therapeutics Inc.** 

**(Exact name of registrant as specified in its charter)** 

________________________________________________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39634** | **47-5271393** |
| **(State or other jurisdiction of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer Identification No.)** |

---

---

| | | | |
|:---|:---|:---|:---|
| **500 Technology Square, Ste 700** | **500 Technology Square, Ste 700** | **500 Technology Square, Ste 700** | |
| | **Cambridge,** | **MA** | **02139**  |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

**(Registrant's telephone number, including area code): (617) 586-3100**

**Not Applicable** 

**(Former name or former address, if changed since last report)** 

________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, $0.0001 par value per share** | **FHTX** | **The Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 17, 2025, Foghorn Therapeutics Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The following proposals were submitted to the Company's stockholders at the Annual Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) &nbsp;&nbsp;&nbsp;&nbsp;To elect Stuart Duty, Neil J. Gallagher, M.D., Ph.D., Adrian Gottschalk, and Ian F. Smith, as Class II directors, each for a three-year term; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.

The proposals are described in detail in the Company's Proxy Statement filed with the U.S. Securities and Exchange Commission on May 5, 2025.

The number of shares of common stock entitled to vote at the Annual Meeting was 55,721,340. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 43,369,822. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;Election of directors.

---

| | | | |
|:---|:---|:---|:---|
| **Director Nominee** | **Votes For** | **Votes Against** | **Abstentions** |
| Stuart Duty | 34619374 | 58073 | 12667 |
| Neil J. Gallagher, M.D., Ph.D. | 34644188 | 35153 | 10773 |
| Adrian Gottschalk | 33534048 | 1132490 | 23576 |
| Ian F. Smith | 30911283 | 3754839 | 23992 |

---

There were 8,679,708 broker non-votes regarding the election of directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;Ratification of selection of independent registered public accounting firm.

Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the voting included 43,340,301 votes for, 16,978 votes against and 12,543 abstentions. There were no broker non-votes regarding this proposal.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **FOGHORN THERAPEUTICS INC.** | **FOGHORN THERAPEUTICS INC.** |
| By: | /s/ Kristian Humer |
|  | Kristian Humer |
|  | Chief Financial Officer |

---

Date: June 17, 2025